Metabolic Syndrome and Bipolar Disorder: What Should Psychiatrists Know?

CNS Neuroscience and Therapeutics

Volumn 18, Issue 2, 2012, Pages 160-166

  de Almeida, Karla M ^a   Moreira, Camila L R L ^a   Lafer, Beny ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bipolar disorder; Cardiovascular disease; Metabolic syndrome; Neuropsychopharmacology

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMOTRIGINE; LITHIUM; LOOP DIURETIC AGENT; METFORMIN; MOOD STABILIZER; OLANZAPINE; PIOGLITAZONE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; PSYCHOTROPIC AGENT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; ANTIHYPERTENSIVE THERAPY; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DIURETIC THERAPY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; METABOLIC SYNDROME X; NEUROPROTECTION; OBESITY; PREVALENCE; PSYCHIATRIST; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; PSYCHIATRY; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 84856804621     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00240.x     Document Type: Review

References (98)

1. Revicki DA, Matza LS, Flood E, Lloyd A. Bipolar disorder and health-related quality of life: Review of burden of disease and clinical trials. Pharmacoeconomics 2005;23:583-594.
2. Bauer MS, Kirk G, Gavin C, Williford W. Correlates of functional and economic outcome in bipolar disorder: A prospective study. J Affect Disord 2001;65:231-241.
3. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005;293:2528-2530.
4. Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders-a national population-based study. Headache 2008;48:501-516.
5. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: Epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005;17:83-93.
6. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:1-14.
7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
8. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
9. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: An international perspective. J Affect Disord 2010;126:366-387.
10. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
11. Reilly MP, Rader DJ. The metabolic syndrome: More than the sum of its parts? Circulation 2003;108:1546-1551.
12. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
13. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375:181-183.
14. Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens 2009;11:761-765.
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
16. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-443.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
18. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-252.
19. Available from: [Accessed 6 August 2010].
20. Monteiro CA, Conde WL, Popkin BM. Income-specific trends in obesity in Brazil: 1975-2003. Am Public Health 2007;97:1808-1812.
21. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541-1545.
22. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424-430.
23. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007;98:247-252.
24. Birkenaes AB, Søgaard AJ, Engh JA, et al. Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. J Clin Psychiatry 2006;67:425-433.
25. Garcia-Portilla MP, Saiz PA, Benabarre A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008;106:197-201.
26. Teixeira PJR, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psichiatr 2007;29:330-336.
27. Salvi V, Albert U, Chiarle A, Soreca I, Bogetto F, Maina G. Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry 2008;30:318-323.
28. Fagiolini A, Frank E, Turkin S, Houck PR, Soreca I, Kupfer DJ. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry 2008;69:678-679.
29. Cardenas J, Frye MA, Marusak SL, et al. Modal subcomponentes of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008;106:91-97.
30. Van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008;10:342-348.
31. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, Miller DD, Haynes WG. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry 2008;20:131-137.
32. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008;10:788-797.
33. Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic syndrome in bipolar disorder: A cross-sectional assessment of a Health Management Organization database. Bipolar Disord 2008;10:607-616.
34. Almeida KM, Macedo-Soares MB, Isller CK, Amaral JA, Caetano SC, Dias RS, Lafer B. Obesity and metabolic syndrome in Brazilian patients with bipolar disorder. Acta Neuropsychiatr 2009;2:84-88.
35. Yumru M, Savas E, Gergelioglu S, Basarali K, Kalenderoglu A, Savas HA, Buyukbas S. The relationship of metabolic syndrome, serum leptin levels and treatment in bipolar disorder. Bull Clin Psychopharmacol 2008;18:79-83.
36. Vuksan-Cusa B, Marcinko D, Nad S, Jakovljević M. Differences in cholesterol and metabolic syndrome between bipolar disorder men with and without suicide attempts. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:109-112.
37. Chang HH, Chou CH, Chen PS, et al. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord 2009;117:124-129.
38. Lee NY, Kim SH, Cho B, et al. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1243-1249.
39. Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71:1138-1144.
40. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry 2006;67:1034-1041.
41. Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, de Burguera M, et al. Lithium and body weight gain. Pharmacopsychiatry 1995;28:35-44.
42. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study. Diabetologia 2005;48:215-221.
43. Pylvänen V, Pakarinen A, Knip M, Isojärvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006;8:643-648.
44. Graham KA, Cho H, Brownley KA, Harp JB. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008;101:287-294.
45. Kretschmer E. Physique and character, 2nd ed. New York: Harcourt, Brace, & Company, 1936.
46. Raphael T, Parsons I. Blood sugar studies in dementia precox and manic-depressive insanity. Arch Neurol Psychiatry 1921;5:681-709.
47. Räikkönen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: A comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care 2007;30:872-877.
48. Kilbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007;9:443-452.
49. Garcia-Portilla MP, Saiz PA, Benabarre A, et al. Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatr Scan 2010;121:437-445.
50. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: Does cortisol play a role? Biol Psychiatry 2004;55:1-9.
51. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry 2010;71:1488-1501.
52. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496-502.
53. Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995;38:797-802.
54. Knijff EM, Breunis MN, van Geest MC, et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord 2006;8:740-750.
55. Rosmond R, Björntorp P. The hypothalamic- pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J Intern Med 2000;247:188-197.
56. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007;104:91-95.
57. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009;116:214-217.
58. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: A systematic review of the literature. J Clin Psychiatry 2009;70:1078-1090.
59. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997;17:2167-2176.
60. Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001;357:763-767.
61. Hamer M, Steptoe A. Association between physical fitness, parasympathetic control, and proinflammatory responses to mental stress. Psychosom Med 2007;69:660-666.
62. Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by Genome-Wide Association. Genomics 2008;92:265-272.
63. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
64. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO expert consultation. Diabetologia 2010;53:600-605.
65. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: Selective clinical review. CNS Drugs 2009;23:1003-1021.
66. Ng F, Mammen OK, Wilting I, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009;11:559-595.
67. Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: A survey of 500 US psychiatrists. Psychopharmacol Bull 2007;40:22-37.
68. Bauer M, Lecrubier Y, Suppes T. Awareness of metabolic concerns in patients with bipolar disorder: A survey of European psychiatrists. Eur Psychiatry 2008;23:169-177.
69. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007;39:1423-1434.
70. Birt J. Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 2003;15:49-58.
71. Netz Y, Dwolatzky T, Zinker Y, Argov E, Agmon R. Aerobic fitness and multidomain cognitive function in advanced age. Int Psychogeriatr 2010;22:1-11.
72. Geda YE, Roberts RO, Knopman DS, et al. Physical exercise, aging, and mild cognitive impairment: A population-based study. Arch Neurol 2010;67:80-86.
73. Gomez-Pinilla F, Ying Z. Differential effects of exercise and dietary docosahexaenoic acid on molecular systems associated with control of allostasis in the hypothalamus and hippocampus. Neuroscience 2010;168:130-137.
74. Sylvia LG, Ametrano RM, Nierenberg AA. Exercise treatment for bipolar disorder: Potential mechanisms of action mediated through increased neurogenesis and decreased allostatic load. Psychother Psychosom 2010;79:87-96.
75. Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008;193:101-107.
76. Mauri M, Simoncini M, Castrogiovanni S, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry 2008;41:17-23.
77. Alvarez-Jiménez M, Martínez-García O, Pérez-Iglesias R, Ramírez ML, Vázquez-Barquero JL, Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res 2010;116:16-19.
78. Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-77.
79. Astrup A, Toubro S. Topiramate: A new potential pharmacological treatment for obesity. Obes Res 2004;12(Suppl):167S-173S.
80. Available from: [Accessed 6 August 2010].
81. Available from: [Accessed 6 August 2010].
82. Benazzi F. Depression induced by orlistat (Xenical). Can J Psychiatry 2000;45:87.
83. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: A critical review. Drug Saf 2008;31:53-65.
84. Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat. Epilepsia 2006;47:2207.
85. Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 2002;22:68-70.
86. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010;75:335-340.
87. McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007;9:426-434.
88. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1698-1706.
89. Kemp DE, Ismail-Beigi F, Calabrese JR. Antidepressant response associated with pioglitazone: Support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry 2009;166:619.
90. Chitturi S, George J. Hepatotoxicity of commonly used drugs: Nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002;22:169-183.
91. Berner JE. Statins can produce ataxia in bipolar disorder: Two case reports. J Clin Psychiatry 2010;71:359.
92. Webber MA, Mahmud W, Lightfoot JD, Shekhar A. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 2004;18:432-434.
93. Giner V, Muñoz R, Redón J. Risperidone and severe cerivastatin-induced rhabdomyolysis. J Intern Med 2002;251:177-178.
94. Furst BA, Champion KM, Pierre JM, Wirshing DA, Wirshing WC. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry 2002;51:264-265.
95. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995;29:172-191.
96. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res 2010;123:225-233.
97. Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006;163:1199-1201.
98. Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: Pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008;118:4-18.